DDInter1605 DDInter1676
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Risperidone {u} (Compound) resembles {v} (Compound) Dapiprazole
Risperidone {u} (Compound) binds {v} (Gene) ADRA1B
Risperidone {u} (Compound) upregulates {v} (Gene) UBQLN2
Risperidone {u} (Compound) palliates {v} (Disease) schizophrenia
Risperidone {u} (Compound) downregulates {v} (Gene) ACAT2
Risperidone {u} (Compound) causes {v} (Side Effect) Manic psychosis
Risperidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ranitidine
Risperidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Risperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ipratropium
Risperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Histrelin
Risperidone (Compound) resembles Dapiprazole (Compound)
Risperidone (Compound) binds ADRA1B (Gene)
Risperidone (Compound) upregulates UBQLN2 (Gene)
Risperidone (Compound) palliates schizophrenia (Disease)
Risperidone (Compound) downregulates ACAT2 (Gene)
Risperidone (Compound) causes Manic psychosis (Side Effect)
Risperidone may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Risperidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin